Targeted Oncology

Targeted Healthcare Communications is at the forefront of the increasing interest in cancer-related products within precision medicine. We proudly hold the distinction of being the first publisher to feature a peer-reviewed journal dedicated to these innovative products. Our offerings include a specialized website, two journals, and a variety of multichannel programs that all concentrate on precision medicine in the field of oncology. Our publication, Targeted Therapies in Oncology™, is committed to equipping oncology healthcare professionals with the latest research, data, and treatment methods related to molecular and immune system targets that can enhance patient outcomes in cancer care. We aim to make the latest developments in diagnostic testing, biomarkers, pathways, immunotherapy, and targeted treatments more accessible for clinical application. The Journal of Targeted Therapies in Cancer™ focuses on elevating cancer patient care by publishing peer-reviewed clinical articles that delve into advancements in cancer targets and targeted therapies, along with their practical applications. Our goal is to broaden oncologists' understanding of biomarkers, pathways, diagnostics, immunotherapy, and targeted therapies, while also providing strategies for personalizing treatment to achieve better patient outcomes. TargetedOnc.com™ is a distinctive resource that emphasizes molecular biology, featuring expert insights on research, management, and treatment. This oncology-centered website is dedicated to providing content that highlights precision medicine in the field. As cancer research shifts towards systems biology and molecular irregularities, many oncologists face the challenge of keeping their knowledge up to date with the evolving landscape of cancer therapeutics.

International, National, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#339713

United States

#144675

Health/Health Conditions and Concerns

#337

Traffic sources

Monthly visitors

Articles

Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in PD-L1+ TNBC

3 days ago | targetedonc.com | Jordyn Sava

The combination of sacituzumab govitecan-hziy (Trodelvy) plus pembrolizumab (Keytruda) significantly improved progression-free survival (PFS) compared with pembrolizumab and chemotherapy when used for the treatment of patients with inoperable, locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS ≥ 10), meeting the primary end point of the phase 3 ASCENT-04/KEYNOTE-D19 trial (NCT05382286).1 Topline results from the ASCENT-04/KEYNOTE-D19 study also...
Leighl Covers PALOMA-3 Trial of SC Amivantamab in NSCLC

6 days ago | targetedonc.com | Jordyn Sava

For patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) progressing after osimertinib (Tagrisso) and chemotherapy, the PALOMA-3 trial (NCT05388669) compared subcutaneous (SC) amivantamab-vmjw (Rybrevant) plus lazertinib (Lazcluze) to the intravenous (IV) regimen.
Bria-IMT Plus Retifanlimab Shows Promising Survival in HR+ Breast Cancer

6 days ago | targetedonc.com | Jordyn Sava

Preliminary results from a phase 2, open-label trial (NCT03328026) indicate a potential survival benefit with the combination of Bria-IMT (SV-BR-1-GM), an off-the-shelf, targeted, cell-based immunotherapy, and immune checkpoint inhibition in patients with heavily pretreated metastatic hormone receptor-positive (HR+) breast cancer.1The study enrolled a cohort of patients with heavily pretreated HR+ metastatic breast cancer (n = 25) who had received a median of 6 prior lines of systemic therapy.
FDA Clears IND Application for CLD-201 in Solid Tumors

1 week ago | targetedonc.com | Jordyn Sava

The FDA has cleared the investigational new drug (IND) application for CLD-201 for the treatment of adult patients with solid tumors. CLD-201 is an investigational, allogeneic stem cell-based immunotherapy. Preclinical findings support this IND for the treatment of solid tumors, including breast cancer, head and neck cancer, and soft tissue sarcoma.
Well-Tolerated TLX101 Shows Efficacy in Recurrent Glioma

1 week ago | targetedonc.com | Jordyn Sava

Treatment with TLX101 (131I-iodofalan) was well tolerated and showed encouraging efficacy data when used for the treatment of patients with recurrent high-grade glioma, including glioblastoma, according to preliminary results from the phase 2 IPAX-Linz study.1The median overall survival (OS) in the IPAX-Linz trial was 12.4 months from the initiation of treatment with TLX101, and the median OS from initial diagnosis was 32.2 months.
Novel Radioenhancer JNJ-1900 Shows Potential Across Cancers

1 week ago | targetedonc.com | Jordyn Sava

JNJ-1900 (NBTXR3) shows potential as an innovative approach to enhance local tumor control without escalating systemic toxicity across solid tumors, including lung cancer, according to preliminary findings from an ongoing phase 1 study (NCT03589339) presented at the 2025 European Lung Cancer Congress (ELCC).1This novel radioenhancer, composed of functionalized hafnium oxide nanoparticles, is designed to amplify the effectiveness of radiation therapy.
Savolitinib/Osimertinib Yields Durable Responses in EGFR-Mutated, MET+ NSCLC

1 week ago | targetedonc.com | Jordyn Sava

Combination therapy with the MET tyrosine kinase inhibitor savolitinib plus osimertinib (Tagrisso) led to high and durable response rates and was well tolerated for the treatment of patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) and MET-overexpression or -amplification following progressive disease, according to data from the phase 2 SAVANNAH trial (NCT03778229) presented at the 2025 European Lung Cancer Congress.1 Among patients treated with the combination (n = 80),...
SGX301 Shows Rapid and Durable Responses in Early-Stage CTCL

1 week ago | targetedonc.com | Jordyn Sava

SGX301 (HyBryte) continues to show promise in early-stage cutaneous T-cell lymphoma (CTCL), with interim results from an extended treatment study titled FLASH2 (NCT06470451) revealing a 75% "treatment success" rate after 18 weeks.1Interim data from the first 9 enrolled patients, with complete week 18 data available for 8 of them, reveal encouraging outcomes.
FDA Backs Darovasertib Phase 3 Trial Design in Uveal Melanoma

1 week ago | targetedonc.com | Jordyn Sava

A successful Type D meeting between the FDA and IDEAYA Biosciences discussed the design of a phase 3 registrational trial evaluating darovasertib for primary uveal melanoma. Darovasertib is a potent and selective protein kinase C (PKC) inhibitor being developed as a neoadjuvant therapy for primary uveal melanoma. The planned phase 3 trial will evaluate the safety and efficacy of neoadjuvant darovasertib in patients with primary uveal melanoma.
First Patient Receives KSQ-004EX for Advanced Cancer

1 week ago | targetedonc.com | Jordyn Sava

A phase 1/2 trial evaluating KSQ-004EX, a novel CRISPR-engineered tumor infiltrating lymphocyte (eTIL) therapy, has dosed its first patient with an advanced solid tumor.1This first patient was enrolled by Rodabe Amaria, MD, professor of melanoma medical oncology and principal investigator of the study at The University of Texas MD Anderson Cancer Center. “The promise of TIL therapy remains high, but current approaches fall short of addressing the needs of most patients with solid tumors.